-
公开(公告)号：US08703140B2
公开(公告)日：2014-04-22
申请号：US11843617
申请日：2007-08-22
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/544 , C07K2317/34 , C07K2317/76 , C07K2319/30
摘要： Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
-
公开(公告)号：US20110229497A1
公开(公告)日：2011-09-22
申请号：US13120125
申请日：2009-09-22
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K16/18 , A61K38/00 , A61K38/1709 , A61K38/177 , C07K14/4721 , C07K2317/54 , C07K2317/55 , C07K2319/70 , C12N9/88 , C12Y402/01002
摘要： Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
摘要翻译： 本文提供了组合物，包括药物组合物和调节，即刺激或抑制替代补体途径的活性的方法，以及鉴定因子H结合蛋白的方法。
-
公开(公告)号：US09815890B2
公开(公告)日：2017-11-14
申请号：US13805522
申请日：2011-06-22
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , C07K14/47
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
-
4.发明授权Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles 有权使用CR2靶向纳米颗粒的非侵入性检测补体介导的炎症公开(公告)号：US08840868B2
公开(公告)日：2014-09-23
申请号：US13148028
申请日：2010-02-04
CPC分类号： A61K49/1812 , A61K49/16 , A61K49/1863 , A61K49/1866 , A61K49/1875 , A61K49/1887 , B82Y5/00
摘要： Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided.
摘要翻译： 提供补体介导炎症的非侵入性成像方法。 还提供了包括用于这些方法的CR靶向超小超顺磁性纳米颗粒或其聚集体的组合物。
-
公开(公告)号：US20130078245A1
公开(公告)日：2013-03-28
申请号：US13589079
申请日：2012-08-17
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
摘要翻译： 本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向预防性或 治疗剂可以与身体内的组织的局部区域相比，其可以以非靶向的系统方式与相同或相似的药物的给药相比，其可以更直接地将其作用发挥到预定的靶细胞或组织上，具有减少的相关系统效应。 因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。 本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。
-
公开(公告)号：US08937046B2
公开(公告)日：2015-01-20
申请号：US13120125
申请日：2009-09-22
CPC分类号： C07K16/18 , A61K38/00 , A61K38/1709 , A61K38/177 , C07K14/4721 , C07K2317/54 , C07K2317/55 , C07K2319/70 , C12N9/88 , C12Y402/01002
摘要： Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
摘要翻译： 本文提供了组合物，包括药物组合物和调节，即刺激或抑制替代补体途径的活性的方法，以及鉴定因子H结合蛋白的方法。
-
公开(公告)号：US20130129728A1
公开(公告)日：2013-05-23
申请号：US13805522
申请日：2011-06-22
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
摘要翻译： 本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向诊断的方法和材料， 预防和治疗剂可以与身体内组织的局部区域直接发挥作用，与预定的靶细胞或组织相比，以相对于或相似的药物以非靶向的系统方式施用相比，具有减少的相关系统效应。 因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。 本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。
-
公开(公告)号：US09650447B2
公开(公告)日：2017-05-16
申请号：US13697693
申请日：2011-05-13
CPC分类号： C07K19/00 , C07K14/472
摘要： Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.
-
公开(公告)号：US08540997B2
公开(公告)日：2013-09-24
申请号：US13162434
申请日：2011-06-16
IPC分类号： A61K39/00
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
公开(公告)号：US08007804B2
公开(公告)日：2011-08-30
申请号：US10534772
申请日：2003-11-13
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.034 秒)
